A negative Signatera test means no circulating tumor DNA (ctDNA) was detected in your blood at the time of the draw. In practical terms, the test found no molecular evidence that cancer cells are actively present in your body. For many patients, especially those recently treated for cancer, this is reassuring news, but understanding what it does and doesn’t guarantee requires some context.
How the Test Works
Signatera is a blood test designed to detect tiny traces of cancer DNA floating in your bloodstream. Unlike standard imaging like CT scans or MRIs, which look for visible tumors, Signatera searches for fragments of DNA that cancer cells shed as they grow and die. It’s personalized: before the test can be used, your original tumor tissue is sequenced to identify 16 genetic mutations unique to your cancer. Those 16 mutations become your custom panel, essentially a molecular fingerprint for your specific cancer.
When your blood is drawn, the lab looks for those exact mutations. If two or more of the 16 tracked mutations show up in the blood sample, the result is positive. If fewer than two are found, the result is negative. The test can pick up tumor DNA at extremely low concentrations, down to 0.01% of the DNA in your blood, making it one of the most sensitive tools available for catching what oncologists call minimal residual disease (MRD): cancer too small to see on a scan but potentially still present at a molecular level.
What a Negative Result Tells You
A negative result means the test did not find your cancer’s molecular fingerprint circulating in your blood. This is a strong signal. In colorectal cancer, one of the most studied cancers for this technology, patients who tested negative on serial blood draws over three years had a recurrence rate as low as 3%, translating to a negative predictive value of 97%. In bladder cancer, the test showed 98% specificity for detecting recurrence after surgery in one study.
In breast cancer, a long-term study tracking patients for up to 12 years after surgery found that of 122 patients who never relapsed, 116 were consistently ctDNA-negative across 941 blood draws. Persistently negative results strongly correlated with staying cancer-free. For patients living with the anxiety of possible recurrence, repeated negative results over time can offer meaningful peace of mind.
What a Negative Result Does Not Rule Out
A negative Signatera test is not a guarantee that you are cancer-free. There are several reasons the test might come back negative even when cancer cells are still present somewhere in your body.
Some tumors simply don’t shed much DNA into the bloodstream. This varies by cancer type and even by individual tumor biology. Triple-negative breast cancers, for instance, tend to shed more DNA because of their high cell turnover, making them easier to detect. Hormone receptor-positive breast cancers shed less, and in one study, all four patients whose relapses were missed by the test had this subtype. Researchers still don’t fully understand why some tumors release detectable amounts of DNA while others remain molecularly silent.
Tumor location matters too. Cancers in certain “sanctuary sites,” like the brain, may not release DNA into the general bloodstream as readily, potentially leading to a negative blood test despite active disease. Small, slow-growing tumors may also fall below the test’s detection threshold.
Timing plays a role as well. If blood is drawn too soon after surgery, residual tumor DNA may not yet be circulating at detectable levels. Current evidence suggests waiting at least two weeks after surgery, with many clinicians historically preferring four weeks or more to reduce the chance of a false negative.
Why Repeat Testing Matters More Than a Single Result
A single negative test is a snapshot. Serial testing, meaning repeated blood draws over months and years, gives your oncologist a much more complete and reliable picture. The difference is significant. In kidney cancer patients under surveillance, those who were serially negative on multiple tests almost all remained progression-free during follow-up. In contrast, one patient who had four consecutive negative results later tested positive on two subsequent draws, prompting imaging that confirmed the cancer had progressed. That case illustrates both the power and the limitations of any single time point.
The real clinical value of Signatera lies in tracking trends. A string of negative results over time is far more reassuring than any individual negative test. Conversely, a shift from negative to positive on a subsequent draw can flag recurrence months before it would appear on a CT scan. In colorectal cancer, Signatera detected recurrence an average of 8.7 months earlier than imaging, with some cases detected up to 16.5 months ahead. Serial monitoring is what unlocks that early warning capability.
How Negative Results Affect Treatment Decisions
One of the biggest questions patients have after a negative result is whether they can skip or shorten chemotherapy. This is an active and evolving area of oncology, but the honest answer right now is that negative results alone are not yet a standard basis for changing treatment plans. Most studies to date have been observational, meaning researchers tracked ctDNA results alongside standard care without using those results to guide therapy. Multiple clinical trials are underway testing whether it’s safe to reduce treatment for ctDNA-negative patients, but those results are still maturing.
Some oncologists do factor Signatera results into their clinical reasoning, particularly when deciding how aggressively to pursue additional therapy in borderline situations. But guidelines haven’t yet formally incorporated ctDNA-guided treatment de-escalation as standard practice. If your test is negative and you’re wondering whether you still need a recommended course of treatment, that’s a conversation worth having with your oncologist, who can weigh the test result alongside your cancer’s stage, biology, and other risk factors.
What to Expect From the Testing Schedule
Your first post-surgical Signatera test is typically drawn two to four weeks after surgery. Research in colorectal cancer has shown that testing as early as two weeks post-surgery has similar sensitivity to waiting four to eight weeks, though your oncologist may adjust the timing based on your specific situation. After that initial draw, most monitoring schedules involve repeat testing every three to six months, often for several years. The exact frequency depends on your cancer type, stage, and treatment plan.
Each blood draw is straightforward: a standard venous blood sample, no different from routine lab work. Results typically take one to two weeks. If you receive a negative result, your care team will likely continue the scheduled monitoring cadence rather than stopping testing altogether, precisely because the value of this tool comes from watching for changes over time rather than relying on any single result.